Here are five updates on GI companies from the past week.
UnitedHealthcare announced it would cover Exact Sciences' Cologuard test starting July 1, causing Exact Sciences' shares to jump 12 percent,
OrphoMed completed a $39 million round of series A financing for the development of its irritable bowel syndrome with diarrhea drug ORP-101.
Eisai Co. presented the results of its phase III trial for its anticancer agent lenvatinib mesylate at the American Society of Clinical Oncology's annual meeting, June 2 to June 6 in Chicago. Researchers evaluated quality of life via questionnaire. Lenvatinib delayed quality of life deterioration.
Takeda Canada inaugurated its new Ontario-based headquarters May 30. Takeda Canada is relocating from its previous Oakville, Ontario office to a larger space, also in Oakville.
A study published in Surgical Endoscopy examined the efficacy of Mederi's endoscopic radiofrequency procedure Stretta in managing gastroesophageal reflux disease. After taking Stretta, only 49 percent of patients using proton pump inhibitors required the inhibitors at follow-up.